» Articles » PMID: 21359659

Cystatin C - a Fast and Reliable Biomarker for Glomerular Filtration Rate in Head and Neck Cancer Patients

Abstract

Purpose: Determination of renal function is a prerequisite for planning therapy in cancer patients. Limitations of creatinine as marker for the glomerular filtration rate (GFR) led to the proposal of cystatin C as a more accurate biomarker especially in mild renal insufficiency or in patients with low muscle mass. We compared the accuracy of cystatin C- and creatinine-based equations to estimate GFR in head and neck cancer (HNC) patients receiving platinum-based radiochemotherapy.

Patients And Methods: The study population consisted of 52 HNC patients (GFR range, 37-105 mL/min/1.73 m(2) complemented by 17 patients with known renal insufficiency (GFR range, 10-60 mL/min/1.73 m(2)). Intraclass correlation coefficients were calculated between the reference method (51)Cr-EDTA clearance and estimated GFR by creatinine clearance and equations based on creatinine (Cockroft-Gault, modification of diet in renal disease (MDRD), Wright) or cystatin C (Larsson, Dade-Behring, Hoek). In addition, sensitivity and specificity to discriminate GFR > 60 mL/min/1.73 m(2) were evaluated by receiver operating characteristic curve (ROC).

Results: The highest correlation coefficients were found for the cystatin C-based estimates in comparison with creatinine-based estimates or creatinine clearance, even though Bland-Altman plots revealed GFR overestimation for all equations tested. The cystatin C-based Hoek formula exhibited the highest overall precision and accuracy. GFR of < 60 mL/min/1.73 m(2) was assumed as a cut-off for chemotherapy. ROC analyses revealed the highest AUC to predict a GFR > 60 mL/min/1.73 m(2) for the creatinine-based Wright formula, closely followed by the MDRD formula and cystatin C-based equations of Larsson, Dade-Behring, and Hoek.

Conclusion: Cystatin C-based GFR estimates showed the overall strongest correlation to the reference method. Thus, we recommend cystatin C for GFR estimation in HNC patients as an alternative method to the estimated creatinine clearance in clinical practice.

Citing Articles

Role of cystatin C in urogenital malignancy.

Ding L, Liu Z, Wang J Front Endocrinol (Lausanne). 2023; 13:1082871.

PMID: 36589819 PMC: 9794607. DOI: 10.3389/fendo.2022.1082871.


Association between socioeconomic position and cystatin C in the Heinz Nixdorf Recall Study.

Zamrik T, Frank M, Emmel C, Rump L, Erbel R, Jockel K Sci Rep. 2021; 11(1):19387.

PMID: 34588554 PMC: 8481271. DOI: 10.1038/s41598-021-98835-7.


Serum Cystatin C as a Potential Marker for Glomerular Filtration Rate in Patients with Cholangiocarcinoma.

Ciin M, Proungvitaya T, Limpaiboon T, Roytrakul S, Chaon U, Tummanatsakun D Int J Hematol Oncol Stem Cell Res. 2020; 14(3):157-166.

PMID: 33024521 PMC: 7521392. DOI: 10.18502/ijhoscr.v14i3.3723.


Evaluation of Serological Indicators and Glomerular Filtration Rate Equations in Chinese Cancer Patients.

Tong Y, Liu X, Guan M, Wang M, Zhang L, Dong D Med Sci Monit. 2017; 23:2949-2960.

PMID: 28623247 PMC: 5486681. DOI: 10.12659/msm.902138.


Individualizing pharmacotherapy in patients with renal impairment: the validity of the Modification of Diet in Renal Disease formula in specific patient populations with a glomerular filtration rate below 60 ml/min. A systematic review.

Eppenga W, Kramers C, Derijks H, Wensing M, Wetzels J, De Smet P PLoS One. 2015; 10(3):e0116403.

PMID: 25741695 PMC: 4351004. DOI: 10.1371/journal.pone.0116403.


References
1.
Wolff H, Bosch J, Jung K, Overbeck T, Hennies S, Matthias C . High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer. Strahlenther Onkol. 2010; 186(5):262-8. DOI: 10.1007/s00066-010-2136-z. View

2.
Patterson W, Reams G . Renal toxicities of chemotherapy. Semin Oncol. 1992; 19(5):521-8. View

3.
Park H, Ju E, Jo S, Jung U, Kim S, Yee S . Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice. BMC Cancer. 2009; 9:85. PMC: 2666758. DOI: 10.1186/1471-2407-9-85. View

4.
Studer G, Seifert B, Glanzmann C . Prediction of distant metastasis in head neck cancer patients: implications for induction chemotherapy and pre-treatment staging?. Strahlenther Onkol. 2008; 184(11):580-5. DOI: 10.1007/s00066-008-1951-y. View

5.
Sakata K, Someya M, Hori M, Nakata K, Takagi M, Hareyama M . Hyperfractionated accelerated radiotherapy for T1,2 glottic carcinoma. Consideration of time-dose factors. Strahlenther Onkol. 2008; 184(7):364-9. DOI: 10.1007/s00066-008-1819-1. View